Onishchenko A L, Kolbasko A V, Safronova M A, Isakov I N
Novokuznetsk State Institute of Postgraduate Medicine, Ministry of Health of the Russian Federation, 5 Stroiteley prospekt, Novokuznetsk, Kemerovo Oblast, Russian Federation, 654005.
Vestn Oftalmol. 2016 May-Jun;132(3):49-51. doi: 10.17116/oftalma2016132349-51.
To study the reasons of intraocular pressure (IOP) resistance to therapy in patients with glaucoma.
During the period 2011-2013 we examined 72 primary glaucoma patients (stage I-III), 44 women and 28 men, aged 49-87 years (65.2±2.5 years on average) referred by local ophthalmologists due to poor response to hypotensive therapy.
We suggest that glaucoma should be regarded as resistant if, despite combination therapy with three antihypertensive drugs at optimal doses, IOP stays above the target. In the present study, the treatment was found suboptimal in 19.4% of cases. About 45% of all patients (33 patients) demonstrated poor compliance to the prescribed treatment. Resistant glaucoma, as we have defined it, was diagnosed in 33% of cases (pigmentary glaucoma, pseudoexfoliation glaucoma, secondary unrecognized glaucoma, etc.). This group also included patients, in whom b-blockers were initially effective, but then seemed to lose their power.
研究青光眼患者眼压治疗抵抗的原因。
在2011年至2013年期间,我们检查了72例原发性青光眼患者(I - III期),其中44例女性,28例男性,年龄49 - 87岁(平均65.2±2.5岁),这些患者由当地眼科医生转诊而来,原因是降压治疗效果不佳。
我们认为,如果尽管使用三种最佳剂量的抗高血压药物联合治疗,眼压仍高于目标值,那么青光眼应被视为治疗抵抗。在本研究中,发现19.4%的病例治疗未达最佳效果。所有患者中约45%(33例患者)对规定治疗的依从性较差。我们所定义的抵抗性青光眼在33%的病例中被诊断出来(色素性青光眼、假性剥脱性青光眼、继发性未识别青光眼等)。该组还包括一些患者,他们最初β受体阻滞剂治疗有效,但后来似乎失效了。